Khondrion Secures up to €5 Million Innovation Credit from Dutch Government plus Additional Funding from Current Investors to Advance Phase 3 Clinical Trial in m.3243A>G Primary Mitochondrial Disease

Government support, alongside private investments, funds first wave of pivotal Phase 3 trial of sonlicromanol for m.3243A>G Primary Mitochondrial Disease (PMD) NIJMEGEN, Netherlands, May 6, 2025 /PRNewswire/ — Khondrion, a clinical-stage biopharmaceutical company pioneering therapies for…